Corporate Information – Page 5 – Alligator Bioscience

2023-11-03

Alligator Bioscience Announces Poster Presentation on Neo-X-Prime Bispecific Antibody ATOR-4066 at SITC Annual Meeting 2023

Presentation highlights ATOR-4066's superior anti-tumor effect and confirms CEACAM5-conditional activation of CD40 expressing cells Dat ...

2023-10-31

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces it will hold a Capital Markets Day on December 1, 2023. ...

2023-10-12

New patent expands protection for mitazalimab in Europe Patent protects composition of matter for mitazalimab until 2038 (including potentia ...

2023-10-05

ATOR-1017, a potential best-in-class 4-1BB monoclonal antibody, demonstrates an excellent preclinical profile with a unique binding site on ...

2023-10-03

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the fo ...

2023-09-28

Clinical and preclinical data from three presentations further demonstrate mitazalimab's ability to activate the immune system and enha ...

2023-09-27

Data demonstrate that mitazalimab induces transcriptomic alterations consistent with immune activation Data reinforce mitazalimab's mod ...

2023-08-21

Regulatory

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Medicines Agency (EMA) has granted Orphan De ...

2023-08-17

Today, on August 17, 2023, the exercise period for warrants series TO 6 in Alligator Bioscience AB (publ) ("Alligator" or the ...